MARKET

RPRX

RPRX

Royalty Pharma Plc
NASDAQ
69.45
+0.68
+0.99%
After Hours: 69.08 -0.37 -0.53% 19:30 11/10 EST
OPEN
68.47
PREV CLOSE
68.77
HIGH
69.63
LOW
67.73
VOLUME
3.42M
TURNOVER
--
52 WEEK HIGH
69.77
52 WEEK LOW
36.80
MARKET CAP
39.84B
P/E (TTM)
45.20
1D
5D
1M
3M
1Y
5Y
1D
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
24/7 Wall St. · 15h ago
Royalty Pharma Earnings Call Highlights Strong Growth
TipRanks · 1d ago
Weekly Report: what happened at RPRX last week (1102-1106)?
Weekly Report · 1d ago
What Comes Next For Royalty Pharma After A 78% Gain
Simply Wall St · 1d ago
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
The Motley Fool · 2d ago
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Seeking Alpha · 3d ago
Royalty Pharma (RPRX) Beat Third Quarter Expectations, Is The Stock Now Overvalued?
Simply Wall St · 3d ago
Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 4d ago
More
About RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.

Webull offers Royalty Pharma plc stock information, including NASDAQ: RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.